Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tormentil for active ulcerative colitis: an open-label, dose-escalating study.

Roman Huber1, Amelie V Ditfurth, Frank Amann

  • 1Department for Internal Medicine II, University Hospital Freiburg, Germany. roman.huber@uniklinik-freiburg.de

Journal of Clinical Gastroenterology
|September 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From information to action: how medical reports can support general practitioners in long-term cancer care-a qualitative exploratory study.

Journal of cancer survivorship : research and practice·2026
Same author

Benign by design: A paradigm shift in cosmetic ingredient development.

International journal of cosmetic science·2026
Same author

Embedding Chemistry and Pharmacy Into Sustainability.

Angewandte Chemie (International ed. in English)·2026
Same author

An interdisciplinary comparative framework for antimicrobial efficacy and environmental risk assessment of antibiotics integrating human and environmental health: a case study from patient to river.

Integrated environmental assessment and management·2026
Same author

Tales of the tides: Pattern-based non-target analysis of the Elbe River.

Journal of hazardous materials·2026
Same author

Dietary intervention among young cancer survivors within the CARE for CAYA program.

Journal of cancer survivorship : research and practice·2026
Same journal

GLP-1 Receptor Agonists and Hepatic Encephalopathy in Cirrhosis: A Protective Signal Requiring Cancer and Nutritional Phenotyping.

Journal of clinical gastroenterology·2026
Same journal

Endoscopic Incisional Therapy for Benign Esophageal Strictures: A Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology·2026
Same journal

International Consensus Statements on the Use of Topical Endoscopic Hemostatic Powders in the Treatment of Acute Gastrointestinal Bleeding.

Journal of clinical gastroenterology·2026
Same journal

Do Risk Factors for Reflux Symptoms After Peroral Endoscopic Myotomy Necessarily Increase the Occurrence of Postoperative Gastroesophageal Reflux?

Journal of clinical gastroenterology·2026
Same journal

Subgroup Stratification by Regimen, Geography, and Population Is Necessary to Validate Nitazoxanide-based Helicobacter pylori Eradication Therapy.

Journal of clinical gastroenterology·2026
Same journal

The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.

Journal of clinical gastroenterology·2026
See all related articles

Tormentil extract (TE) is safe for ulcerative colitis (UC) patients up to 3000 mg/day. TE improved UC symptoms and inflammatory markers, with tannins not being absorbed systemically.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Phytotherapy

Background:

  • Tormentil extract (TE) possesses antioxidant properties and is explored for chronic inflammatory bowel disease.
  • Positive effects of TE have been anecdotally observed in ulcerative colitis (UC) patients.

Purpose of the Study:

  • To evaluate the safety, pharmacology, and clinical efficacy of escalating doses of TE in active UC patients.
  • To assess the impact of TE on clinical activity index (CAI), C-reactive protein, and systemic tannin absorption.

Main Methods:

  • A 16-patient study involving active UC participants with CAI ≥5.
  • Escalating doses of TE (1200-3000 mg/d) administered for 3-week periods, followed by 4-week washout phases.
  • Outcome measures included side effects, CAI, C-reactive protein levels, and serum tannin analysis via LC-MS.

Related Experiment Videos

Main Results:

  • TE was safe up to 3000 mg/d, with mild abdominal discomfort in 38% of patients not requiring treatment cessation.
  • At 2400 mg/d, median CAI and C-reactive protein significantly improved from baseline.
  • CAI decreased during TE therapy and increased during washout, indicating a treatment effect. No systemic tannin absorption was detected.

Conclusions:

  • Tormentil extract is safe and well-tolerated in active UC patients at doses up to 3000 mg/d.
  • Systemic absorption of tannins from TE was not detected, suggesting a localized effect.
  • Further clinical trials are warranted to confirm the efficacy of TE for UC treatment.